Search

Background: Despite the primary myelin-related pathophysiology, small fiber neuropathy (SFN) and axonal degeneration are also considered to be involved and associated with disabling symptoms and impaired quality of life in chronic inflammatory demyelinating polyneuropathy (CIDP). Demonstration of SFN usually requires complex or invasive investigations. Objects: In vivo corneal confocal microscopy (IVCCM) has evolved as a non-invasive, easily applied method for quantification of small fiber involvement in peripheral nerve disorders. We aimed to investigate the potential role of IVCCM in CIDP. Methods: In this cross-sectional study, 15 patients with CIDP underwent assessment with clinical disability scales, neuropathic pain (NP) and autonomic symptom questionnaires, nerve conduction studies, and IVCCM. IVCCM parameters were analyzed and compared to those from 32 healthy controls. Results: Corneal nerve fiber density (CNFD) and corneal nerve fiber length (CNFL) were significantly decreased in the CIDP group, compared to those in controls (p = 0.03 and p = 0.024, respectively). Langerhans cells and fiber tortuosity were increased in CIDP patients (p = 0.005 and p = 0.001, respectively). IVCCM parameters were significantly lower in patients with NP compared to those in patients without NP. Conclusion: IVCCM shows promise as a non-invasive complementary biomarker in the assessment of demyelinating polyneuropathies, providing insights into the potential pathophysiology of these non-length-dependent neuropathies. [ABSTRACT FROM AUTHOR]

Purpose: To evaluate reading performance, preferred reading distance, and spectacle independence in patients implanted with a low add multifocal or an extended depth of focus (EDOF) intraocular lens (IOL) after phacoemulsification. Methods: In this prospective study, patients were randomized into two groups: the diffractive multifocal Tecnis + 2.75 D (ZKB00) IOL (Tecnis + 2.75 group; 15 patients) or the EDOF Tecnis Symfony (ZXR00) IOL (Symfony group; 14 patients) for bilateral implantation with mini-monovision. Reading performance parameters (reading acuity [RA], critical print size [CPS], and maximum reading speed [MRS]) were evaluated with MNREAD acuity charts at 40 cm, and preferred reading distances and spectacle independence for near activities were assessed preoperatively and at the postoperative 1st, 3rd, and 6th months. Results: At the postoperative 6th month, binocular logMAR UNVA and DCNVA were significantly better in the Symfony group than in the Tecnis + 2.75 group (UNVA: 0.15 ± 0.07 vs. 0.22 ± 0.08, p = 0.046; DCNVA: 0.21 ± 0.05 vs. 0.28 ± 0.07, p = 0.043; respectively). There was no significant difference in reading performance parameters between the groups; however, the Symfony group preferred significantly closer reading distance than the Tecnis + 2.75 group (42.00 ± 4.67 cm; 45.87 ± 5.32 cm, respectively, p = 0.030). At the postoperative 6th month, 14.3% and 26.7% of patients reported that they needed spectacles, rarely or occasionally, for near activities in the Symfony and Tecnis + 2.75 groups, respectively (p > 0.05). Conclusions: When implanted with mini-monovision, although functional near visual acuity and a high degree of spectacle independence at near distances were achieved with both IOLs, patients implanted with the EDOF IOL preferred closer reading distance than those implanted with the low add diffractive multifocal IOL. [ABSTRACT FROM AUTHOR]

Purpose: Primary ocular adnexal lymphomas are cured by radiotherapy; however, complications are frequent and relapses may occur. In this case, we aimed to report the efficacy and safety of extended systemic rituximab (anti-CD 20 monoclonal antibody) therapy of conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma.Methods: In the standard regimen, rituximab is used as four consecutive weekly infusions of 375 mg/m2 in patients with low-grade lymphomas. We treated a patient who had bilateral conjunctival MALT lymphoma with rituximab 375 mg/m2 intravenously once weekly for 10 weeks as a first-line therapy.Results: During the examination of the sixth week, we observed partial response of the lesions in both eyes. At the end of the tenth cure, complete remission was achieved. No local or systemic adverse effect was observed. The patient has no signs of recurrence during the 22-months follow-up period.Conclusion: Extended rituximab therapy may be an effective and well-tolerated first-line treatment option for bilateral conjunctival MALT lymphoma. [ABSTRACT FROM AUTHOR]

The original article has been corrected, Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. B Correction to b B : b B Neurological Sciences (2023) b https://doi.org/10.1007/s10072-023-06711-1 The original article contains an error during online publication: 1. [Extracted from the article]

The objective of the study is to investigate the effect of hydroxychloroquine (HCQ) on subjective and objective parameters of dry eye in patients with primary Sjogren's disease and to evaluate the association of tear fluid B-cell activating factor (BAFF) level with the response. Thirty-two patients with primary Sjogren's disease were enrolled in this prospective study. All patients included in the study completed at least a 48-month run-in period of using hydroxychloroquine. Patients were then instructed to drop the treatment for 3 months. Baseline and post cessation of treatment (baseline and 3 months) evaluations included, subjective symptom scoring, fluorescein and lissamine green staining, Schirmer's test, tear break-up time (BUT) and tear fluid BAFF assessments. Significant worsening was observed in, tear break up-time (TBUT) (7.9 ± 3.4 vs. 5.9 ± 2.9, P < 0.001) lissamine green of staining of the ocular surface (1.3 ± 0.9 vs. 1.8 ± 0.8, P < 0.01) and corneal fluorescein staining scores (2.2 ± 2.1 vs. 4.6 ± 3.3, P < 0.003) between on and off HCQ treatment, respectively. Similarly, gritty sensation and burning sensation were significantly changed at week 12 compared to baseline evaluation (1.18 ± 1.02 vs. 1.7 ± 1.05, P < 0.007 and 1.1 ± 1.0 vs. 1.6 ± 1.2, P < 0.0, respectively). Disease duration significantly correlated with baseline OSDI ( r = 0.38, P < 0.04) and the average daily use of artificial tears ( r = 0.36, P < 0.04). The mean BAFF levels were 0.8 ± 0.5 and 4.0 ± 0.7 ng/ml for baseline and week 12 evaluation, respectively ( P < 0.0001). The results of this study suggest that HCQ may alleviate symptoms and signs of dry eye in pSS and decreases tear fluid BAFF levels. [ABSTRACT FROM AUTHOR]

To translate the original 42-item National Eye Institute Refractive Error Quality of Life Questionnaire (NEI-RQL-42) into Turkish and to investigate its validity and reliability. The linguistic translation followed the international guidelines of forward and backward translation. Ninety-five consecutive subjects (37 myopes, 18 hyperopes and 40 emmetropes) who had a visual acuity of 0.8 or better in the worse eye completed the NEI-RQL-42 and the Turkish version of the 25-item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25). Eighty patients completed the NEI-RQL-42 for a second time within 2 weeks. Psychometric evaluation of the Turkish NEI-RQL-42 involved the assessment of internal consistency, test–retest reliability, convergent and known-groups validity. Internal consistency was generally high (Cronbach’s α = 0.83–0.95), with the exception of three subscales (glare, α = 0.65; suboptimal correction, α = 0.66; appearance, α = 0.62). Test–retest reliability, assessed by the intraclass correlation coefficient was good (ICC = 0.74–0.95) except for the subscale suboptimal correction (ICC = 0.61). Almost all subscales and the overall score showed significant inter-correlations. Low to moderate correlations were found between the subscales of the NEI-RQL-42 and the NEI-VFQ-25, which measure similar constructs. The NEI-RQL-42 showed good construct validity in terms of refractive error (myopia, hyperopia and emmetropia) and mode of refractive correction (spectacles, contact lens and no correction) discrimination. The Turkish version of the NEI-RQL-42 is a reliable and valid measure of vision-related quality of life in patients with refractive error. [ABSTRACT FROM AUTHOR]

Purpose: In this study we investigated the presence of soluble VCAM-1 and soluble L-selectin-1 in subretinal fluids (SRF) of patients suffering from rhegmatogenous retinal detachment . Method: Subretinal fluids were collected from drainage sclerotomies during surgery from 27 patients with rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy (PVR) or uncomplicated retinal detachment. Levels of sVCAM-1 and sL-selectin-1 were quantified with ELISA. Results: The mean ± SEM values of sVCAM-1 and sL-selectin-1 were 222.2 ± 81 ng/ml and 171.7 ± 42.1 ng/ml, respectively. The concentrations of sVCAM-1 in patients with Grade C PVR (498.2 ± 170 3 ng/ml) were significantly different from those with Grade B PVR (45.6 ± 16.5 ng/ml) and uncomplicated retinal detachments (19.4 ± 12.3 ng/ml). SVCAM-1 concentration in detachments which had been present for more than 8 weeks was 738.8 ± 431 ng/ml, significantly higher than the levels in detachments of shorter duration (132.4 ± 47.7 ng/ml). sL-selectin-1 level in Grade C PVR (291.6 ± 92.8 ng/ml) was higher than in uncomplicated retinal detachments (72.8 ±13.5 ng/ml). Significantly elevated levels of sL-selectin-l were observed in detachments lasting more than 8 weeks (605 ± 151.1 ng/ml) compared to those of shorter duration (96.3 ± 13.1 ng/ml). Conclusion: The present study supports growing evidence that these cell adhesion molecules are involved in the inflammatory process during the development and progression of PVR. [ABSTRACT FROM AUTHOR]